The Kaplan-Meier estimate of the proportion of patients reaching the PROactive main secondary endpoint of deaths from any cause, non-fatal myocardial infarction (excluding silent myocardial infarction) or stroke shows that more patients (n=358) reached one of these three components in the placebo group than in the pioglitazone group (301 patients).
This equates to a hazard ratio of 0.84 or a 16% relative risk reduction and the difference was statistically significant (95% CI: 0.72, 0.98; p=0.0273).